NCCN Guidelines for Patients
Peripheral T-cell Lymphoma, Version 1.2016
lists first-line treatment options for
enteropathy-associated T-cell lymphoma. Joining
a clinical trial that is right for your disease is the
preferred option of the NCCN experts. If a clinical
trial isn’t an option, a second option is 6 cycles of
a standard chemotherapy regimen. Regimens are
listed in the chart. You may also receive involved-site
radiation therapy to lower your chances of the cancer
After chemotherapy, the results need to be assessed
with testing. Any imaging test that showed cancer
before treatment should be repeated. If PET/CT still
shows signs of cancer, a biopsy is needed to confirm
before receiving more treatment.
There are three options if testing finds no signs of
cancer. The first option is to join a clinical trial of
additional drug treatment or of a stem cell transplant.
You must be fairly healthy to undergo a transplant.
The second option is to receive an autologous stem
cell transplant outside of a clinical trial. Before or after
the high-dose chemotherapy portion of the transplant,
you may receive radiation therapy. A transplant is
an option because there is some proof that it may
improve results, but better research is needed.
The third option is observation. Observation or
“watch-and-wait” is a period of testing to assess for
changes in cancer status. If signs of cancer appear
during observation, see Chart 4.4.2 for treatment
options that don’t include a transplant or Chart 4.4.3
for treatment options that do include transplant.
If testing finds cancer after 6 cycles of chemotherapy,
you have treatment options. Your options depend on
whether you can and want to undergo a stem cell
transplant. If a stem cell transplant will not be part of
your treatment, see Chart 4.4.2. Treatment options
in Chart 4.4.3 are for people who plan to have a
lists second-line options that don’t
include a stem cell transplant. Second-line treatment
is received when first-line treatment didn’t work or
the cancer came back. Options include joining a
clinical trial, drug treatment, and radiation therapy
as supportive care. Supportive care aims to reduce
symptoms of cancer.
Enteropathy-associated T-cell lymphoma